Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know.
Inspire Medical Systems beat analysts’ revenue expectations by 2.6% last quarter, reporting revenues of $203.2 million, up 32.5% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Is Inspire Medical Systems a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Inspire Medical Systems’s revenue to grow 23.4% year on year to $237.5 million, slowing from the 39.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.72 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Inspire Medical Systems has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3.1% on average.
Looking at Inspire Medical Systems’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Haemonetics delivered year-on-year revenue growth of 3.7%, missing analysts’ expectations by 1.3%, and Intuitive Surgical reported revenues up 25.2%, topping estimates by 6.5%. Haemonetics traded down 16.7% following the results while Intuitive Surgical was also down 4%.
Read our full analysis of Haemonetics’s results here and Intuitive Surgical’s results here.
Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Inspire Medical Systems is up 3.8% during the same time and is heading into earnings with an average analyst price target of $238.80 (compared to the current share price of $182.13).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.